▲ Peaking
Business
Foghorn lays off 40% of employees as Lilly cancer collab collapses over poor data
Foghorn Therapeutics faces severe downsizing and stock downgrades after the collapse of its cancer partnership with Lilly.
Fhd-909
1 trends tracked about this subject — the full history, oldest to newest below.